Journal
SAGE OPEN MEDICAL CASE REPORTS
Volume 8, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/2050313X20940430
Keywords
Pyoderma gangrenosum; secukinumab; biologics; treatment
Categories
Ask authors/readers for more resources
Pyoderma gangrenosum is a challenging disease to manage, due in part to the lack of approved treatment therapies. Recently, the emergence of biologic agents has expanded treatment options, with tumour necrosis factor alpha inhibitors being the best supported in the literature. In our report, we present a 50-year-old female with pyoderma gangrenosum who was successfully treated with the anti-interleukin-17 biologic agent, secukinumab, after failing other systemic therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available